AACR Conference Coverage
Filter News By:
Featured News
View all
More News
(MSK) Apr 14, 2021 - Three Memorial Sloan Kettering experts shared important research findings in plenary talks during Week 1 of the American Association for Cancer Research’s (AACR) virtual Annual Meeting 2021, held from April 10 to...
(Yahoo! Finance) Apr 15, 2021 - Poster includes analysis of results by liver metastases, further strengthening results reported in December 2020 of the COMBAT/KEYNOTE-202 triple combination study of motixafortide in metastatic pancreatic...
(ABC News/AP) Apr 12, 2021 - A drug that helps the immune system fight cancer gave dramatic results when used with chemotherapy before surgery in patients with operable lung tumors, doctors report. One out of 4 patients given chemo and...
(BeiGene) Apr 12, 2021 - The global Phase 3 trial achieved its primary endpoint, with tislelizumab significantly prolonging overall survival in all patients, regardless of PD-L1 status. Tislelizumab was generally well-tolerated,...
(AACR) Apr 12, 2021 - The American Association for Cancer Research (AACR) welcomes David A. Tuveson, MD, PhD, FAACR, as President of the organization for 2021-2022.
(MD Anderson Cancer Center) Apr 12, 2021 - Novel approach paves the way for vast expansion in the number of drugs targeting osteosarcoma.
(AACR/Cancer Research Catalyst) Apr 10, 2021 - This year at the AACR Annual Meeting, the premier cancer meeting in the world, data from clinical trials testing the latest cancer treatments were featured in three Clinical Trial Plenary...
(AACR) Apr 10, 2021 - A combination of copanlisib (Aliqopa) and rituximab led to a 48 percent reduction in the risk of disease progression or death compared with placebo and rituximab in patients with relapsed indolent non-Hodgkin...
(Bayer) Apr 10, 2021 - Results from the randomized, double-blind, placebo-controlled Phase III trial CHRONOS-3 show a significant improvement in progression-free survival (PFS) with the investigational combination of Aliqopa® (copanlisib)...
(UCLA Health) Apr 10, 2021 - UCLA clinical trial shows bispecific CAR T cells targeting CD19/CD20 are safe and effective in patients with relapsed or refractory B-cell lymphoma.
Expert Videos
There are no videos.

OBR Tweets

Apr 16
Early Impressions of IMpower010: What Might This Mean for Immunotherapy in Early-Stage Non-Small Cell Lung Cancer?… https://t.co/MwVpuqeCFN

Dec 06
Stephen Ansell, MD, PhD, of @MayoCancerCare on options for lymphoma patients who are refractory to CAR T-cell treat… https://t.co/0in19JpTFM

Dec 06
@TomBmt133 of @UCSFCancer considers the significance of the IKEMA study #ASH20 https://t.co/hPGQ0EeLgx

Dec 06
@MichaelDJain on immunotherapy treatment trends in the management of aggressive lymphomas @MoffittNews #ASH20 https://t.co/9XpyqMU0X3

Dec 06
Bhavana Bhatnagar, DO, regarding data on racial disparities in the treatment of AML from #ASH20 https://t.co/IWQOcPAupf

Sep 24
Cristina Suárez, MD, of @vallhebron offers opinion on whether the CheckMate 9ER trial is practice-changing #ESMO20 https://t.co/6m8UCjJPxE

Sep 24
Andrew Schmidt, MD, @dr_aschmidt of @DanaFarber regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented a… https://t.co/tbmT0twPFA

Sep 24
Erika Hamilton, MD, @ErikaHamilton9 of @SarahCannonDocs regarding the Phase III monarchE trial presented at #ESMO20 https://t.co/AiqtvpEZ7u

Sep 24
Giuseppe Giaccone, PhD, MD, of @WeillCornell regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCL… https://t.co/D5Su3qEkbb

Sep 24
Pasi A. Jänne, MD, PhD, of @DanaFarber shares data from #ESMO20 investigating mobocertinib https://t.co/idTloLVyBj